248 related articles for article (PubMed ID: 1346493)
1. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.
Hait WN; Aftab DT
Biochem Pharmacol; 1992 Jan; 43(1):103-7. PubMed ID: 1346493
[TBL] [Abstract][Full Text] [Related]
2. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
3. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
Ford JM; Prozialeck WC; Hait WN
Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
[TBL] [Abstract][Full Text] [Related]
4. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells.
Hait WN; Gesmonde JF; Murren JR; Yang JM; Chen HX; Reiss M
Biochem Pharmacol; 1993 Jan; 45(2):401-6. PubMed ID: 8094615
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.
Hait WN; Choudhury S; Srimatkandada S; Murren JR
J Clin Invest; 1993 May; 91(5):2207-15. PubMed ID: 8098047
[TBL] [Abstract][Full Text] [Related]
7. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
9. N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.
Safa AR; Agresti M; Bryk D; Tamai I
Biochemistry; 1994 Jan; 33(1):256-65. PubMed ID: 7904476
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection.
Choi K; Frommel TO; Stern RK; Perez CF; Kriegler M; Tsuruo T; Roninson IB
Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7386-90. PubMed ID: 1678523
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines.
Nielsen D; Skovsgaard T
Biochim Biophys Acta; 1992 Jul; 1139(3):169-83. PubMed ID: 1352705
[TBL] [Abstract][Full Text] [Related]
12. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide.
Gupta KP; Ward NE; Gravitt KR; Bergman PJ; O'Brian CA
J Biol Chem; 1996 Jan; 271(4):2102-11. PubMed ID: 8567666
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Gekeler V; Beck J; Noller A; Wilisch A; Frese G; Neumann M; Handgretinger R; Ehninger G; Probst H; Niethammer D
Ann Hematol; 1994; 69 Suppl 1():S19-24. PubMed ID: 7914748
[TBL] [Abstract][Full Text] [Related]
14. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
15. Nuclear DNA content and chromatin texture in multidrug-resistant human leukemic cell lines.
Dufer J; Millot-Broglio C; Oum'Hamed Z; Liautaud-Roger F; Joly P; Desplaces A; Jardillier JC
Int J Cancer; 1995 Jan; 60(1):108-14. PubMed ID: 7814142
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
17. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic circumvention of multidrug resistance.
Ford JM; Hait WN
Cytotechnology; 1993; 12(1-3):171-212. PubMed ID: 7765325
[TBL] [Abstract][Full Text] [Related]
19. An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate.
Bergman PJ; Gravitt KR; O'Brian CA
Cancer Chemother Pharmacol; 1997; 40(5):453-6. PubMed ID: 9272125
[TBL] [Abstract][Full Text] [Related]
20. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
